Adalimumab
- PDF / 168,966 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 46 Downloads / 163 Views
1 S
Pneumonia: case report In a multiregional study of 31 patients conducted as a part of an active pharmacovigilance program by the Italian Medicines Agency (AIFA) for a total duration of 1 year, a patient [exact age and sex not stated] was described, who developed severe pneumonia during treatment with adalimumab for psoriasis [dosage, route, duration of treatment to reaction onset and outcome not stated]. The patient, who had psoriasis, had received treatment with adalimumab. Subsequently, the patient developed severe drug-related pneumonia. Adalimumab was discontinued because of drug-related pneumonia. Vergani HM, et al. Active pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases. International Journal of Clinical Pharmacology and 803515537 Therapeutics 58: 208-213, No. 4, Apr 2020. Available from: URL: http://doi.org/10.5414/CP203628
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
